SCHEMBL3240469

SCHEMBL3240469

CN1CCN(c2ccc(Cl)cc2)c2ccc(-c3ccccn3)cc2C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 3/20 0.50
DRD2 P14416 1/20 0.41
NR1I2 O75469 1/20 0.39
HSD11B1 P28845 1/20 0.39
METAP1 P53582 1/20 0.38
AVPR2 P30518 1/20 0.38
AVPR1A P37288 1/20 0.38
KCNH2 Q12809 1/20 0.38
HRH4 Q9H3N8 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HTR6 P50406 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
LMNA P02545 1/20 0.38
FLT3 P36888 1/20 0.38
MAPKAPK2 P49137 1/20 0.37
GRM5 P41594 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GSK3B P49841 1/20 0.36
DYRK1A Q13627 1/20 0.36
HTR1A P08908 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3220403 0.91 SCN9A (0.51) SCN9ADRD2METAP1SMN1; SMN2HTR6
SCHEMBL3223902 0.89 SCN9A (0.46) SCN9ADRD2METAP1KCNH2HRH4
SCHEMBL3231467 0.89 SCN9A (0.48) SCN9ADRD2METAP1AVPR2AVPR1A
SCHEMBL3224959 0.89 SCN9A (0.52) SCN9ADRD2METAP1HRH4SMN1; SMN2
SCHEMBL3479700 0.87 SCN9A (0.46) SCN9AAVPR2AVPR1AKCNH2HRH4
SCHEMBL3238925 0.87 SCN9A (0.48) SCN9ADRD2METAP1SMN1; SMN2ALDH1A1
SCHEMBL3225109 0.86 SLC6A2 (0.48) SCN9ANR1I2HSD11B1HRH4MAPKAPK2
SCHEMBL3220973 0.86 SCN9A (0.49) SCN9ADRD2METAP1SMN1; SMN2HTR6
SCHEMBL3230176 0.86 SCN9A (0.49) SCN9AAVPR1AHRH4SMN1; SMN2HTR6
SCHEMBL3233722 0.85 SCN9A (0.42) SCN9ADRD2NR1I2HSD11B1METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed
EP-2146722-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR Technology, Inc. (US) 2010-01-27 EP disclosed
WO-2008141081-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR TECHNOLOGY, INC. (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SCN9A 795/4885DRD2 5/4885NR1I2 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.